MVC’s WHO-Partnered Vaccine a First for Taiwan
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
CHUGAI PHARMACEUTICAL CO., LTD- founded in 1925- is committed to providing high-quality healthcare and improving people’s health, well-being and quality of life. With global horizon, Chugai is increasingly focusing on Research and Development (R＆D). Our mission today and tomorrow is to create exceptional added value in healthcare, and proceed to be a leading international health care company.
To service Taiwan, Chugai set up a Taipei branch company in 1988, and merged with HUEY MAW TRADING CO., LTD. to become CHUNG HUEY PHARMACEUTICAL CO., LTD. in 1991. In October 2001, the company officially changed the name to CHUGAI PHARMA TAIWAN and reran the business for marketing hospital-based products. Most of the pharmaceutical products import from Japan headquarters directly and part of them are toll manufacture locally; furthermore, CHUGAI PHARMA TAIWAN CO., LTD and SHUN HWA CO., LTD are responsible for marketing business to remain constant: to improving patient care.
Major products
GRANOCYTE (Recombinant Human Granocyte Colony-Stimulating Factor Preparation)
SIGMART (Anti Angina Pectoris Agent)
Company Name: Chugai Pharma Taiwan Ltd.
Address: 3Fl., No. 73, ZhouZi Street, Neihu District,Taipei 10493, Taiwan
Telephone: (02)2658-8800
Fax: (02)2658-8852
E-Mail: cpt@chugai.com.tw
Website: www.chugai-pharm.co.jp
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
See our Cookie Privacy Policy Here
